Peptic ulcer disease: One in five is related to neither Helicobacter pylori nor aspirin/NSAID intake

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 946-954

  Charpignon, C ^a   Lesgourgues, B ^b   Pariente, A ^c,f   Nahon, S ^b   Pelaquier, A ^d,e   Gatineau Sailliant, G ^a   Roucayrol, A M ^a   Courillon Mallet, A ^a  

^a Villeneuve St Georges Hospital   (France)

^b Montfermeil Hospital   (France)

^c Pau Hospital   (France)

^d Montelimar Hospital   (France)

^e Emergency Department Smur 77   (France)

^f CENTRE HOSPITALIER DE PAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CARBON UREA C 13; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG USE; DUODENITIS; EROSIVE DUODENITIS; ETHNIC GROUP; FEMALE; FRENCH LANGUAGE; GASTROSCOPY; GENERAL HOSPITAL; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; IDIOPATHIC DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREATH TESTS; FEMALE; FRANCE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITALIZATION; HOSPITALS, GENERAL; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84884909767     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12465     Document Type: Article

References (36)

1. Sung JJ, Kuipers EJ, El-Serag HB,. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29: 938-46.
2. Nahon S, Hagège H, Latrive JP, et al,. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy 2012; 44: 998-1008.
3. Malfertheiner P, Chan FKL, McColl KEL,. Peptic ulcer disease. Lancet 2009; 374: 1449-61.
4. Scarpignato C, Hunt RH,. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-64.
5. Nensey YM, Schubert TT, Bologna SD, et al,. Helicobacter pylori-negative duodenal ulcer. Am J Med 1991; 91: 15-8.
6. Borody TJ, Brandl S, Andrews P, et al,. Helicobacter pylori-negative gastric ulcer. Am J Gastroenterol 1992; 87: 1403-6.
7. Sprung DJ, Apter MN,. What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? J Clin Gastroenterol 1998; 26: 60-3.
8. Jyotheeswaran S, Shah AN, Jin HO, et al,. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93: 574-8.
9. Henry A, Batey RG,. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? Aust N Z J Med 1998; 28: 345.
10. Ciociola AA, McSorley DJ, Turner K, et al,. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94: 1834-40.
11. Meucci G, Di Battista R, Abbiati C, et al,. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer: a multicenter study. J Clin Gastroenterol 2000; 31: 42-7.
12. Nishikawa K, Sugiyama T, Kato M, et al,. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000; 12: 635-40.
13. Bytzer P, Teglbjaerg PS,; Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis-results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96: 1409-16.
14. Xia HH, Wong BC, Wong KW, et al,. Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther 2001; 15: 1875-82.
15. Sugiyama T, Nishikawa K, Komatsu Y, et al,. Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci 2001; 46: 307-10.
16. Quan C, Talley NJ,. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97: 2950-61.
17. Aarents NLA, Thijs JC, van Zwet AA, et al,. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur J Gastroenterol Hepatol 2004; 16: 779-83.
18. Hung LC, Ching JY, Sung JJ, et al,. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845-50.
19. Arroyo MT, Forne M, de Argila CM, et al,. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004; 9: 249-54.
20. Jang HJ, Choi MH, Shin WG, et al,. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci 2008; 53: 1527-31.
21. Sbrozzi-Vanni A, Zullo A, Di Giulio E, et al,. Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey. Dig Liver Dis 2010; 42: 773-6.
22. Musumba C, Jorgensen A, Sutton L, et al,. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012; 36: 48-56.
23. Cekin AH, Taskoparan M, Duman A, et al,. The role of Helicobacter pylori and NSAIDs in the pathogenesis of uncomplicated duodenal ulcer. Gastroenterol Res Pract 2012; 2012: 189373.
24. Gisbert JP, Calvet X,. Review article: Helicobacter pylori-negative ulcer disease. Aliment Pharmacol Ther 2009; 30: 791-815.
25. Genta RM, Lew GM, Graham DY,. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6: 281-9.
26. Burucoa C, Delchier JC, Courillon-Mallet A, et al,. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 2013; 18: 169-79.
27. Lanas A, Sekar MC, Hirschowitz BI,. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-9.
28. McColl KE,. How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol 2009; 104: 190-3.
29. Wong GL, Au KW, Lo AO, et al,. Gastroprotective therapy does not improve outcomes of patients with H. pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 2012; 10: 1124-9.
30. Yoon H, Kim SG, Jung HC, Song IS,. High recurrence rate of idiopathic peptic ulcers in long-term follow-up. Gut Liver 2013; 7: 175-81.
31. Laine L, Hopkins R, Girardi L,. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93: 1409-15.
32. Eastwood GL,. Is smoking still important in the pathogenesis of peptic ulcer disease? J Clin Gastroenterol 1997; 25 (Suppl. 1): S80-6.
33. Borody TJ, George LL, Brandl S, et al,. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am J Gastroenterol 1992; 87: 1390-3.
34. Chan FK, Sung JJ, Lee YT, et al,. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? Am J Gastroenterol 1997; 92: 442-5.
35. McColl KE, el-Nujumi AM, Chittajallu RS, et al,. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34: 762-8.
36. Kamada T, Haruma K, Kusunoki H, et al,. Significance of an exaggerated meal-stimulated gastrin response in pathogenesis of Helicobacter pylori-negative duodenal ulcer. Dig Dis Sci 2003; 48: 644-51.